ANTICIPATE-NASH Beats Biopsy for Event Risk in MASLD- Gastroenterology Feb.26
Introduction
In metabolic dysfunction-associated steatotic liver disease (MASLD), fibrosis stage on liver biopsy (F3 vs F4) remains the cornerstone for prognosis, surveillance, and clinical trial eligibility. However, real-world experience tells us that not all F3 patients behave the same, and not all F4 patients decompensate.
This study challenges a long-standing paradigm:
Is histology really the best way to stratify risk in advanced MASLD?
The clinical problem
Biopsy-based fibrosis staging has important limitations:
It is invasive, costly, and prone to sampling variability
It provides a static snapshot, not a dynamic risk estimate
It performs poorly in predicting who will actually develop clinical events
At the same time, portal hypertension—not fibrosis alone—drives outcomes in advanced MASLD.
What the study did:
Evaluated two large multicenter cohorts of patients with biopsy-proven F3–F4 MASLD
Compared traditional histologic staging with the noninvasive ANTICIPATE-NASH models, which estimate risk of:
clinically significant portal hypertension
liver-related clinical events (decompensation, HCC, transplant, death)
Tested whether biopsy added any meaningful prognostic value beyond the models
Validated findings in an independent cohort from randomised clinical trials, using regulatory endpoints
Key findings clinicians should understand
- Noninvasive models clearly outperform histology
ANTICIPATE-NASH stratified the risk of liver-related events far better than F3 vs F4 on biopsy. Histology alone showed limited ability to predict outcomes.
- Biopsy adds no incremental value once the model is known
When ANTICIPATE-NASH risk was included, the fibrosis stage did not improve prediction. In other words, the model already captured what truly matters for prognosis.
- F3 and F4 patients overlap biologically
Some F3 patients had high ANTICIPATE-NASH scores and developed clinical events
Some F4 patients had low scores and remained stable
This highlights why the fibrosis stage alone is an unreliable surrogate for risk.
- Results hold up in clinical trial populations
The superiority of ANTICIPATE-NASH over histology was confirmed using regulatory trial endpoints, strengthening the relevance for drug development.
Why this matters for daily practice
Risk stratification:
Surveillance, intensity of follow-up, and counselling should move beyond biopsy labels.
Clinical trials:
ANTICIPATE-NASH can:
enrich trials with patients likely to experience events
Identify patients more likely to show cirrhosis regression, improving signal detection
Future care models:
This supports a shift from “what stage is the biopsy?” to
“What is the patient’s actual risk?”
Bottom-line takeaway:
In advanced MASLD, noninvasive ANTICIPATE-NASH models predict real clinical outcomes far better than the liver biopsy fibrosis stage. Histology should no longer be considered the gold standard for risk stratification in this population.
One-line GastroAGI takeaway
In MASLD, prognosis is driven by risk, not biopsy stage.
